{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-072851","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.814179+00:00","generated_at":"2026-06-21T18:56:07.467453+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Allarity Therapeutics Q3 net loss of $5M; cash at $3.9M; substantial doubt about going concern","bullets":["Cash $3.9M as of Sept 30, 2022, down from $19.6M at Dec 31, 2021.","Net loss of $5.0M in Q3 2022 vs $1.4M in Q3 2021; R&D expense rose to $3.0M.","Cash insufficient to fund operations beyond Dec 31, 2022; going concern warning issued.","In discussions with Series A preferred holder for bridge loan; no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-072851","json":"https://secwatch.observer/filing/0001213900-22-072851.json","markdown":"https://secwatch.observer/filing/0001213900-22-072851.md","text":"https://secwatch.observer/filing/0001213900-22-072851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/ea168752-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:56:07.467453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc5531a14c1317c0b3ff3e01a8cf3fd765e955f2","claim":"Allarity Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: net income $5.0 million.","evidence_excerpt":"Net loss was $5.0 million for the three months ended September 30, 2022, compared to $1.4 million for the comparable period in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390022072851/0001213900-22-072851-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$5.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}